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Background 
Combretastatin A4 phosphate (CA4P) is a tumour vascular disrupting agent (VDA) that targets 
endothelial microtubules, triggering remodelling of the actin cytoskeleton, contractility and disruption 
of VE-cadherin junctions through RhoGTPase/ROCK-dependent pathways. These events lead to a rise 
in endothelial monolayer permeability. A rise in permeability is considered crucial for vascular 
shutdown elicited by CA4P in vivo. CA4P also inhibits endothelial migration and induces mitotic arrest 
and apoptosis, so potentially it could also target tumour angiogenesis. 
Method 
In this study, the nature of signalling interactions between Rho/ROCK and cAMP/cGMP and their 
influence on cytoskeletal and functional responses of endothelial cells to CA4P were investigated. 
Results 
Several cAMP/cGMP analogues inhibited CA4P-induced Rho/ROCK activation and prevented actin 
remodeling, disruption of cell-to-cell junctions and permeability rise in endothelial monolayers. cAMP 
inhibits Rho by either protein kinase A (PKA)-dependent mechanisms or via activation of Epac1/Rap1. 
O-Me-cAMP, an analogue that selectively activates Epac1/Rap1 abolished activation of Rho/ROCK by 
CA4P while selective PKA activator 6-Bnz-cAMP only partially inhibited Rho/ROCK activation and 
actin remodelling by CA4P. Inhibitors of PKA did not alter endothelial responses to CA4P in the 
presence of cAMP analogues suggesting that cAMP acts primarily via Epac1/Rap1 to inhibit 
Rho/CA4P interactions. CA-4-P also inhibited endothelial migration and abolished lamellipodia at the 
leading edge of migrating cells in injured monolayers. Rho inhibitor C3 exoenzyme and ROCK 
inhibitor Y27632 as well as cAMP analogues re-established cell movement and formation of 
lamellipodia in wounded monolayers exposed to CA-4-P, suggesting that inhibitory effects on 
migration were mediated via Rho/ROCK. 
Conclusion 
Deciphering molecular pathways that modulate endothelial responses to VDAs is important for further 
targeting. Our data demonstrate that interactions between cGMP/cAMP and Rho influence both the 
vascular disrupting and anti-angiogenic activities of CA-4-P and point to cAMP/cGMP as potential 
targets for improving VDA activity. 
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